Concepedia

Author

Akihiko Shimomura

Tokyo National HospitalORCID

Also Known As

A. Shimomura, AKIHIKO SHIMOMURA, Akihiko Shimomura, Yukinori Ozaki

258

Publications

3.6K

Citations

28

H-Index

71

Concepts

All Affiliations

Tokyo National HospitalNational Cancer Center Hospital EastNational Center for Global Health and MedicineToranomon HospitalThe Cancer Institute Hospital
AS

About

Akihiko Shimomura is an author at Tokyo National Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

18

28

1.7K

2

Engineering

3

3

98

3

Health Sciences

2

2

367

4

Biomedical Engineering

1

1

26

5

Biomolecular Engineering

1

1

26

Akihiko Shimomura

×

66

Publications

3.2K

Citations

27

H-Index

YearCitations

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study

Toshihiko Doi, Kohei Shitara, Yoichi Naito,

The Lancet Oncology

2017

474

Novel combination of serum microRNA for detecting breast cancer in the early stage

Akihiko Shimomura, Sho Shiino, Junpei Kawauchi,

Cancer Science

2016

353

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo,

Cancer Science

2019

351

RETRACTED ARTICLE: Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression

Atsunori Kamiya, Yohsuke Hayama, Shigeki Kato,

Nature Neuroscience

2019

283

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer

Atsuko Kitano, Makiko Ono, Masayuki Yoshida,

ESMO Open

2017

156

First-in-Human Phase 1 Study of MORAb-202, an Antibody–Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α–Positive Advanced Solid Tumors

Toshio Shimizu, Yutaka Fujiwara, Kan Yonemori,

Clinical Cancer Research

2021

90

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo,

Molecular Cancer Therapeutics

2019

79

Serum miRNA–based Prediction of Axillary Lymph Node Metastasis in Breast Cancer

Sho Shiino, Juntaro Matsuzaki, Akihiko Shimomura,

Clinical Cancer Research

2018

66

Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer

Yutaka Fujiwara, Kenji Tamura, Shunsuke Kondo,

Cancer Chemotherapy and Pharmacology

2016

61

High-throughput functional evaluation of BRCA2 variants of unknown significance

Masachika Ikegami, Shinji Kohsaka, Toshihide Ueno,

Nature Communications

2020

60

Page 1